IFNB1 and myeloid sarcoma: Severa and colleagues showed that the in vitro exposure to IFN-β rescues the IFN pathway defects in B cells derived from MS patients, sustaining antiviral processes, leading to a reduction of EBV-infected and proliferating B cells (19).